One of the underlying mechanisms is that anti-VEGF therapies can reduce VEGF therapy-mediated immunosuppression within the tumor and its microenvironment may enhance anti-PD-1/PD-L1 efficacy by reversing VEGF-mediated immunosuppression and promoting tumor T-cell infiltration (24). Here, PDCD1 is linked to neoplasm.